PDS Biotechnology Corporation (PDSB)
| Market Cap | 50.26M +10.7% |
| Revenue (ttm) | n/a |
| Net Income | -34.50M |
| EPS | -0.74 |
| Shares Out | 55.82M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 921,474 |
| Open | 0.9300 |
| Previous Close | 0.9281 |
| Day's Range | 0.8606 - 0.9870 |
| 52-Week Range | 0.5068 - 1.9150 |
| Beta | 1.18 |
| Analysts | Strong Buy |
| Price Target | 9.00 (+899.45%) |
| Earnings Date | May 13, 2026 |
About PDSB
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies. The company’s lead product candidate is Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protei... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for PDSB stock is "Strong Buy." The 12-month stock price target is $9.0, which is an increase of 899.45% from the latest price.
News
PDS Biotech Announces Publication of Positive PDS01ADC Interim Phase 2 Clinical Trial Data from Stage 1 of NCI-led Metastatic Colorectal Cancer (mCRC) Trial
78% Objective Response Rate (ORR) with PDS01ADC; Parallel trial without PDS01ADC had 35% ORR 2-year survival rate of >80%; Parallel trial without PDS01ADC resulted in 2-year survival rate of ~35%
PDS Biotechnology Earnings Call Transcript: Q4 2025
Clinical and financial progress included a reduced net loss, lower operating expenses, and key advances in HPV-16 cancer trials. FDA-cleared protocol amendments are expected to accelerate regulatory t...
PDS Biotech Reports Full Year 2025 Financial Results and Provides Update on PDS0101 Phase 3 Program and PDS01ADC Clinical Advancement
Filed Phase 3 Amendment Incorporates PFS as Interim Primary Endpoint Expected to Shorten Trial Duration and Reduce Costs
PDS Biotech Announces Conference Call and Webcast for 2025 Fourth Quarter and Year End Financial Results
PRINCETON, N.J., March 24, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the im...
PDS Biotech Announces Adoption of Amended Protocol for Phase 3 VERSATILE-003 Trial Incorporating Progression Free Survival (PFS) as Primary Endpoint for Interim Analysis and Potential Accelerated Approval
Enables Potential Shorter Time to Accelerated Approval of PDS0101 in HPV16-positive Head and Neck Cancer Enables Potential Shorter Time to Accelerated Approval of PDS0101 in HPV16-positive Head and Ne...
PDS Biotech Announces Presentation of Preliminary Results from Phase 2 Study of IL-12 Tumor Targeted Immunocytokine (PDS01ADC) in 3rd Line Metastatic Castration Resistant Prostate Cancer by the NCI
NCI-Led Study Shows Median PFS of 9.6 Months Results Presented at AACR Special Conference on Innovations in Prostate Cancer
PDS Biotech Announces New U.S. Patent Covering Technology Underlying PDS0101
Patent Enhances IP Estate for Lead Asset; Combined with Anticipated Biologics Exclusivity, Market Protections Extend Over 20 Years Patent Enhances IP Estate for Lead Asset; Combined with Anticipated B...
PDS Biotech Announces FDA Alignment on use of Progression Free Survival (PFS) as Primary Endpoint
PDS Biotech Submits Amended Protocol for Phase 3 VERSATILE-003 Trial Constructive Type C Meeting Provides Potential Pathway to Accelerated Approval of PDS0101 PRINCETON, N.J., Jan. 09, 2026 (GLOBE NEW...
PDS Biotech Announces New Composition of Matter Patent for PDS0101 in Japan
New Patent Grants Broad Composition Claims for PDS0101 Previously Granted Patent Protections and Anticipated Market Exclusivity Provide Protection for PDS0101 in the United States into the 2040s PRINC...
PDS Biotech Announces Scheduling of Type C Meeting with U.S. Food and Drug Administration (“FDA”)
Company to Discuss Proposed Amendment to Phase 3 VERSATILE-003 Trial Enabling Potential Accelerated Approval Pathway Company to Discuss Proposed Amendment to Phase 3 VERSATILE-003 Trial Enabling Poten...
PDS Biotechnology Earnings Call Transcript: Q3 2025
Strong phase 2 survival data in HPV-16 positive head and neck cancer led to a protocol amendment in the phase 3 trial, aiming to accelerate regulatory submission. Net loss narrowed year-over-year, and...
PDS Biotech Reports Third Quarter 2025 Financial Results and Provides Clinical Programs Update
Company Announced Completion of VERSATILE-002 Phase 2 trial of PDS0101 + Pembrolizumab in HPV16-Positive Recurrent/Metastatic Head and Neck Cancer
PDS Biotechnology Announces up to $11.1 Million Registered Direct Offering
PRINCETON, N.J., Nov. 11, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the imm...
PDS Biotechnology Announces Translational Data Showing Strong Immunological and Clinical Activity of PDS0101 and PDS01ADC Presented at SITC 2025
Translational study shows that multiple immunological biomarkers predict the clinical activity of PDS0101 combination therapy PDS01ADC reprograms natural killer (NK) cells to possess characteristics ...
PDS Biotech Announces Conference Call and Webcast for Third Quarter 2025 Financial Results
PRINCETON, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the imm...
New Clinical and Translational Data on PDS Biotechnology's Novel Investigational Cancer Therapies PDS0101 and PDS01ADC to be Presented at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Three abstracts accepted for presentation, including one rapid oral abstract session Presentations to highlight ongoing clinical and translational research across PDS Biotechnology's immunotherapy pla...
PDS Biotech to Seek Expedited Approval Pathway for PDS0101 in HPV16-Positive Head and Neck Cancer
Company aims to shorten time frame to make PDS0101 available to patients with HPV16-positive head and neck cancer, projected to be the most dominant type of head and neck cancer in the US by mid 2030s...
PDS Biotech Sets Significant Benchmark in Head and Neck Cancer by Achieving Extended Survival in Low PD-L1 Expression (CPS 1–19) Cohort in VERSATILE-002 Trial, Potentially Eliminating Need for Chemotherapy in the Population
First combination therapy to report 29.5 months of Median Overall Survival (mOS); Standard of care Keytruda ® (pembrolizumab) alone (10.8 months) and Keytruda ® + chemotherapy (12.3 months) in patient...
PDS Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
PRINCETON, N.J., Sept. 02, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the im...
PDS Biotech Announces Final Topline Survival Data from VERSATILE-002 Phase 2 Trial in Head and Neck Cancer
Median Overall Survival (mOS) of 39.3 months in patients with CPS ≥ 1 – best published result with standard of care pembrolizumab or pembrolizumab + chemotherapy is 17.9 months*
PDS Biotechnology Earnings Call Transcript: Q2 2025
Advanced phase III trial for HPV16-positive head and neck cancer, supported by durable phase II results and strong investigator engagement. Q2 2025 net loss was $9.4M, with reduced operating expenses ...
PDS Biotech Reports Second Quarter 2025 Financial Results and Provides Clinical Programs Update
Multiple Abstracts Presented at the 2025 American Society of Clinical Oncology Annual Meeting Conference call and webcast today at 8:00 a.m. Eastern Time PRINCETON, N.J.
PDS Biotech Announces Conference Call and Webcast for Second Quarter 2025 Financial Results
PRINCETON, N.J., Aug. 06, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the imm...
PDS Biotech Announces Colorectal Cancer Cohort of Phase 2 Clinical Trial with PDS01ADC Met Criteria for Expansion to Stage 2 Following Positive Stage 1 Results
PRINCETON, N.J., July 10, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the imm...
PDS Biotechnology Transcript: Status Update
HPV 16 positive head and neck cancer incidence is rising, with current therapies often inadequate. The VERSATILE-002 trial showed promising survival and response rates for pembrolizumab plus PDS0101, ...